**Background of ANXA4 Antibody**
The ANXA4 antibody targets Annexin A4 (ANXA4), a member of the annexin family of calcium-dependent phospholipid-binding proteins. ANXA4 plays roles in membrane-related processes, including vesicle trafficking, signal transduction, and cell proliferation/apoptosis regulation. It is widely expressed in epithelial tissues, such as the kidney, lung, and gastrointestinal tract, and is implicated in maintaining membrane integrity and calcium homeostasis.
In cancer research, ANXA4 has gained attention due to its overexpression in various malignancies, including ovarian, colorectal, and pancreatic cancers. It is associated with chemoresistance, tumor progression, and metastasis, making it a potential biomarker or therapeutic target. ANXA4 antibodies are essential tools for detecting its expression and localization in cells or tissues via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies help elucidate ANXA4's role in pathological processes and its interaction with signaling pathways, such as PI3K/AKT and MAPK.
Researchers must validate ANXA4 antibodies for specificity, as isoforms within the annexin family share structural similarities. Applications vary based on antibody clonality (monoclonal vs. polyclonal) and epitope recognition. Reliable ANXA4 antibodies are critical for advancing studies in cancer biology, drug resistance mechanisms, and diagnostic development.